Halberd Corp Stock Price, News & Analysis

Halberd Corporation (OTC PINK:HALB) announced the shipment of samples of metallic nanoparticles conjugated to Alzheimer's Disease antibodies to Youngstown State University. This follows promising initial tests involving metal conjugated antibodies against E. coli. The next step is eradicating these conjugated AD building blocks using Halberd's proprietary laser eradication process. CEO William Hartman stated that further development will focus on proteins associated with PTSD and Chronic Traumatic Encephalopathy. The company is also awaiting a more powerful radio frequency unit for parallel experimentation.

Halberd Corporation (OTC PINK: HALB) has shifted focus from COVID-19 research to tackling Alzheimer's Disease and other conditions due to decreased COVID cases. Collaboration with Youngstown State University and others aims to develop proprietary antibody technologies. Stock performance declined in Q2; however, plans for an OTCQB listing, launching an immune support product (Vita-Shield-Max™), and innovative research are expected to boost future performance. The company has filed multiple patents to strengthen its market position.

Halberd Corporation (OTC PINK:HALB) announces a breakthrough method for removing disease-causing antigens without using antibody-conjugated metallic nanoparticles. This new technique utilizes standard medical equipment, promising to lower treatment costs and simplify stock management. The initial focus will be Alzheimer's Disease, targeting key antigens and inflammatory cytokines. The development process is expedited by provisional patent applications. CEO William A. Hartman expressed optimism about market acceptance and commercial opportunities, enhancing Halberd's potential for growth.

Halberd Corporation (OTC PINK:HALB) has advanced its proprietary technology to Stage 4 in tackling Alzheimer's Disease, a condition impacting over 40 million globally. The company's method aims to eliminate the antibody-disease complex using radiofrequency waves and lasers. Steps 1-3 have been completed, with Step 4 in progress at Youngstown State University, overseen by Dr. William G. Sturrus. Halberd's team is addressing unique challenges to ensure the efficacy of their treatment. The company has expanded its target antigens list, enhancing success probability.

Halberd Corporation (OTC PINK:HALB) has developed a novel method for extricating Alzheimer's Disease-related proteins from Cerebral Spinal Fluid (CSF) using gold-coated iron oxide nanoparticles.

This technique aims to combat neurofibrillary tangles linked to Alzheimer's Disease, with initial tests planned at Youngstown State University using E.coli. The company is advancing towards animal safety tests, focusing on eradicating harmful antigens from CSF to potentially slow the disease's progression. The projected increase in Alzheimer's cases reinforces the significance of this research.

Halberd Corporation (OTC PINK:HALB) has initiated groundbreaking experiments aimed at eradicating key components of Alzheimer's Disease. The company intends to target three critical antigens linked to neurofibrillary tangles using a patented extracorporeal treatment process, which operates directly on cerebrospinal fluid. Halberd has secured antibodies against Tau, Phosphorylated Tau, and Beta Amyloid and is in the process of conjoining metallic nanoparticles to enhance their efficacy. CEO William A. Hartman expressed confidence in their methodology, emphasizing its potential to transform Alzheimer's treatment.

Halberd Corporation (OTC PINK:HALB) has announced the development of two new neutralizing antibodies against the SARS-CoV-2 Spike Protein, exhibiting greater binding affinity compared to previous antibodies. These antibodies target different regions of the Spike protein, enhancing the potential effectiveness of treatments when combined with existing antibody cocktails. The company is progressing with its patented extracorporeal treatment process aimed at eradicating disease antigens. Step 4 of their development roadmap is currently underway, focusing on effectiveness against SARS-CoV-2 and E. coli bacteria.

Halberd Corporation (OTC PINK:HALB) has filed a U.S. provisional patent application for an innovative technology aimed at treating and detecting SARS-CoV-2 using antibody-conjugated nanoparticles. Developed through research at Arizona State University, this technology allows for the elimination of viruses via radio waves and enhances the ability to detect viral load in patients. The CEO emphasized the broader application of this method for various infections, aiming for wide-ranging treatment capabilities.

Halberd Corporation (OTC PINK:HALB) announced a significant breakthrough in pathogen eradication. The company successfully conjugated gold-coated iron nanoparticles with E. coli antibodies, a vital step in eliminating bacteria from bodily fluids using radio frequency and laser energy. E. coli is a major cause of spinal infections and blood sepsis, responsible for nearly 250,000 deaths in the U.S. annually. The research, led by Dr. Shawn Q. Chen, shows promise for treating antibiotic-resistant bacteria and aims to reduce side effects compared to conventional therapies.